Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany’s Digital Health Fast-Track Scheme: What Manufacturers Need To Know

Executive Summary

Understanding the German reimbursement system is crucial for any medtech firm eyeing the European market, and healthtech innovators in particular may benefit from its fast-track digital health app scheme. But how does the scheme work, and who can apply?

You may also be interested in...



The Serious Business Of Digital Medical Games

There are fewer than a handful of approved prescription video game digital therapeutics, but gamification in patient care is proving its worth as a novel way of treating a range of conditions, from vision loss to dyslexia and ADHD. Now, the onus is on lawmakers and insurers to create a clear path towards reimbursement.

Belgian Research Reveals Extent Of EU’s Digital Health Tech Reimbursement Labyrinth

Digital medical products pose challenges beyond the scope of existing evaluation frameworks for medical devices, triggering proactive responses at both a national and EU-level. A report by Belgian researchers shows just how complex the situation is.

Payment Schemes For Innovative Medtech Exist In Just 8 European Countries - Report

Innovative medtech products should receive reimbursement based on the value they add to the health care system, but just eight European countries offer funding pathways at present, analysis by MedTech Europe and Med Tech Reimbursement Consulting shows.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT146014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel